Metabolomics Holds Promise in Identifying Parkinson's Disease Before Onset

Researchers from the Harvard T.H. Chan School of Public Health have found that metabolomics, the study of the unique chemical fingerprints that specific cellular processes leave behind, may hold the key to identifying Parkinson's disease before diagnosis. The study, published in Movement Disorders, analyzed plasma metabolomic profiles from 922 individuals with Parkinson's disease and compared them to those of matched controls. The results suggest that certain metabolites, including amino acids, acyl-carnitines, and lipids, may be associated with Parkinson's disease, particularly in the years leading up to diagnosis.

Key Takeaways:

• The study analyzed plasma metabolomic profiles from 922 individuals with Parkinson's disease and compared them to those of matched controls to identify potential biomarkers for the disease.
• Certain metabolites, including amino acids, acyl-carnitines, and lipids, were nominally associated with Parkinson's disease, particularly in the years leading up to diagnosis.
• Metabolomic profiles in prodromal samples were unable to accurately predict future clinical Parkinson's disease.
• Metabolic pathways related to the metabolism of amino acids and lipids may be involved in Parkinson's disease progression.
• The study found that metabolites reflected higher intake of coffee, smoking, and acetaminophen tended to be associated with a lower Parkinson's disease risk over the course of the disease.
• Metabolomic differences may also result from behavioral changes and medical management, emphasizing the need to consider prodromal and clinical data in future studies.

Statistics:

• 922 individuals with Parkinson's disease participated in the study, providing blood samples at a median of 11 years before (n = 809) or 2 years after (n = 113) disease diagnosis.
• Metabolites proposed as biomarkers of foods or care products tended to be associated with a higher Parkinson's disease risk closer to disease diagnosis.
• The study used conditional logistic regression models and machine learning techniques to identify metabolites predicting prodromal and clinically manifest Parkinson's disease.

Sources:

• NewsRx. Study Findings from Harvard T.H. Chan School of Public Health Broaden Understanding of Parkinson's Disease (Plasma Metabolomics Profiles In Prodromal and Clinical Parkinson's Disease). Cancer Weekly. October 21, 2025; p 881.
• Plasma Metabolomics Profiles In Prodromal and Clinical Parkinson's Disease. Movement Disorders, 2025.
• Movement Disorders can be contacted at: Wiley, 111 River St, Hoboken 07030-5774, NJ, USA. (Wiley-Blackwell - www.wiley.com/; Movement Disorders - onlinelibrary.wiley.com/journal/10.1002/(ISSN)1531-8257)